November 7, 2008
DOR BioPharma to Present at the Biotech 2008 Conference
DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced today that it has been chosen to make a corporate presentation at the Biotech 2008 conference at 2:30 p.m. on Monday, November 10th, 2008 at the Loews Philadelphia Hotel.
In its eighth year, Biotech 2008 is a tri-state conference featuring innovative and emerging biotechs in New Jersey, Pennsylvania and Delaware. DOR is one of 14 companies chosen to provide corporate presentations. Adam Rumage, Director of Regulatory & Clinical Operations at DOR, will provide a company overview highlighting its lead product, orBec(R) (oral beclomethasone dipropionate or BDP), being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation (HCT).
Biotech 2008, to be held on November 10th-11th, 2008, will feature top executives from the region's global pharmaceutical, biotech, medical device, and diagnostic companies; venture capitalists and other investors; university researchers; university-industry liaison officers; government officials; and support organizations. The event is organized by BioNJ and Pennsylvania Bio.
About DOR BioPharma, Inc.
DOR BioPharma, Inc. (DOR), headquartered in Ewing, New Jersey, is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec(R) (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation.
DOR maintains two business segments: BioTherapeutics and BioDefense. DOR's business strategy is to (a) work with the FDA on the design of a confirmatory Phase 3 clinical trial in GI GVHD; (b) make orBec(R) available worldwide through named patient access programs for the treatment of GI GVHD; (c) explore acquisition strategies under which the Company may be acquired by another company with oncologic or GI symmetry; (d) identify a development and/or marketing partner for orBec(R) for territories both inside and outside of the US; (e) conduct a Phase 2 clinical trial of orBec(R) for the prevention of GVHD; (f) evaluate and initiate additional clinical trials to explore the effectiveness of oral BDP in other therapeutic indications involving inflammatory conditions of the GI tract such as chronic GVHD, radiation enteritis, radiation injury and Crohn's disease; (g) reinitiate development and manufacturing of its other biotherapeutics products, namely LPM(TM) Leuprolide; (h) continue to secure additional government funding for each of its biodefense programs, RiVax(TM) and BT-VACC(TM), through grants, contracts and procurements; (i) convert its biodefense vaccine programs from early stage development to advanced development and manufacturing with the potential to collaborate and/or partner with other companies in the biodefense area; and (i) acquire or in-license new clinical-stage compounds for development.
For further information regarding DOR BioPharma, Inc., please visit the Company's website at www.dorbiopharma.com.
This press release contains forward-looking statements that reflect DOR BioPharma, Inc.'s current expectations about its future results, performance, prospects and opportunities. Statements that are not historical facts, such as "anticipates,""believes,""intends," or similar expressions, are forward-looking statements. These statements are subject to a number of risks, uncertainties and other factors that could cause actual events or results in future periods to differ materially from what is expressed in, or implied by, these statements. DOR cannot assure you that it will be able to successfully develop or commercialize products based on its technology, including orBec(R), particularly in light of the significant uncertainty inherent in developing vaccines against bioterror threats, manufacturing and conducting preclinical and clinical trials of vaccines, and obtaining regulatory approvals, that its cash expenditures will not exceed projected levels, that it will be able to secure partnerships or obtain financing within the next six months to meet operating expenses and to conduct its upcoming confirmatory Phase 3 trial of orBec(R), that product development and commercialization efforts will not be reduced or discontinued due to difficulties or delays in clinical trials or due to lack of progress or positive results from research and development efforts, that it will be able to successfully obtain any further grants and awards, maintain its existing grants which are subject to performance, enter into any biodefense procurement contracts with the US Government or other countries, that the US Congress may not pass any legislation that would provide additional funding for the Project BioShield program, that it will be able to patent, register or protect its technology from challenge and products from competition or maintain or expand its license agreements with its current licensors, or that its business strategy will be successful. Important factors which may affect the future use of orBec(R) for gastrointestinal GVHD include the risks that: the FDA's requirement that DOR conduct additional clinical trials to demonstrate the safety and efficacy of orBec(R) will take a significant amount of time and money to complete and positive results leading to regulatory approval cannot be assumed; DOR is dependent on the expertise, effort, priorities and contractual obligations of third parties in the clinical trials, manufacturing, marketing, sales and distribution of its products; orBec(R) may not gain market acceptance if it is eventually approved by the FDA; and others may develop technologies or products superior to orBec(R). These and other factors are described from time to time in filings with the Securities and Exchange Commission, including, but not limited to, DOR's most recent reports on Forms 10-Q and 10-KSB. Unless required by law, DOR assumes no obligation to update or revise any forward-looking statements as a result of new information, future events.
Company Contact: Evan Myrianthopoulos Chief Financial Officer (609) 538-8200 www.dorbiopharma.com DOR BioPharma, Inc. 850 Bear Tavern Road, Suite 201 Ewing, NJ 08628
SOURCE: DOR BioPharma, Inc.